These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32977745)

  • 21. Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe.
    Stoner MCD; Mathebula F; Sedze N; Seyama L; Mohuba R; Fabiano Z; Etima J; Young A; Scheckter R; van der Straten A; Piper J; Noguchi L; Montgomery ET; Balán IC
    AIDS Behav; 2024 Jul; 28(7):2264-2275. PubMed ID: 38526641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa.
    Medina-Marino A; Bezuidenhout D; Ngwepe P; Bezuidenhout C; Facente SN; Mabandla S; Hosek S; Little F; Celum CL; Bekker LG
    J Int AIDS Soc; 2022 Jul; 25(7):e25968. PubMed ID: 35872602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.
    Mugwanya KK; Pintye J; Kinuthia J; Abuna F; Lagat H; Begnel ER; Dettinger JC; John-Stewart G; Baeten JM;
    PLoS Med; 2019 Sep; 16(9):e1002885. PubMed ID: 31479452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
    Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
    Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
    Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women's preferences for HIV prevention service delivery in pharmacies during pregnancy in Western Kenya: a discrete choice experiment.
    Mugambi ML; Odhiambo BO; Dollah A; Marwa MM; Nyakina J; Kinuthia J; Baeten JM; Weiner BJ; John-Stewart G; Barnabas RV; Hauber B
    J Int AIDS Soc; 2024 Jul; 27 Suppl 1(Suppl 1):e26301. PubMed ID: 38965978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the Integration of Syndromic versus Etiological Management of Sexually Transmitted Infections Into HIV Pre-Exposure Prophylaxis Services for Adolescent Girls and Young Women, in South Africa.
    Mullick S; Cox LA; Martin CE; Fipaza Z; Ncube S
    J Adolesc Health; 2023 Dec; 73(6S):S67-S72. PubMed ID: 37953011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.
    Minnis AM; Roberts ST; Agot K; Weinrib R; Ahmed K; Manenzhe K; Owino F; van der Straten A;
    AIDS Behav; 2018 Aug; 22(8):2662-2673. PubMed ID: 29560570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
    Nicol E; Ramraj T; Hlongwa M; Basera W; Jama N; Lombard C; McClinton-Appollis T; Govindasamy D; Pass D; Funani N; Aheron S; Paredes-Vincent A; Drummond J; Cheyip M; Dladla S; Bedford J; Mathews C
    PLoS One; 2022; 17(3):e0264808. PubMed ID: 35298487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    Montgomery ET; Atujuna M; Krogstad E; Hartmann M; Ndwayana S; OʼRourke S; Bekker LG; van der Straten A; Minnis AM
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):542-550. PubMed ID: 30865050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preferences for oral PrEP dosing among adolescent boys and young men in three sub-Saharan African countries.
    Kakande A; Ssemata AS; Muhumuza R; Atujuna M; Abaasa A; Ndekezi D; Tshabalala G; Nematadzira T; Hornschuh S; Nomvuyo M; Ahmed N; Maluadzi M; Anne Weiss H; Webb E; Stranix-Chibanda L; Janine Dietrich J; Seeley J; Fox J
    PLoS One; 2023; 18(10):e0285132. PubMed ID: 37812644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding women and men's acceptability of current and new HIV prevention technologies in KwaZulu-Natal, South Africa.
    Govender E; Abdool Karim Q
    AIDS Care; 2018 Oct; 30(10):1311-1314. PubMed ID: 29914270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review and Economic Analysis of the Dapivirine Vaginal Ring as HIV Pre-Exposure Prophylaxis for Women, to Inform South African Public-Sector Guidelines.
    Leong TD; Nel J; Jamieson L; Osih R; Dawood H; Subedar H; McCaul M; Johnson LF; Cohen K
    J Acquir Immune Defic Syndr; 2024 Nov; 97(3):261-272. PubMed ID: 39051791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A; Stadler J; Luecke E; Laborde N; Hartmann M; Montgomery ET;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19146. PubMed ID: 25224610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Women and ARV-based HIV prevention - challenges and opportunities.
    Geary CW; Bukusi EA
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19356. PubMed ID: 25224621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa.
    Vazquez L; Moll AP; Kacin A; Ndlovu NE; Shenoi SV
    AIDS Patient Care STDS; 2019 May; 33(5):214-219. PubMed ID: 31067125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.